Article Information
History
- October 17, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sweta Rajpal1,2,
- Gaurav Chatterjee1,2,
- Prasanna Bhanshe1,
- Vishram Terse1,
- Swapnali Joshi1,
- Shruti Chaudhary1,
- Dhanalaxmi Shetty4,2,
- Purvi Mohanty4,2,
- Chetan Dhamne3,2,
- Prashant Tembhare1,2,
- Shyam Srinivasan3,2,
- Akanksha Chichra3,2,
- Nirmalya Roy Malik3,2,
- Shripad Banavali3,2,
- Sumeet Gujral1,2,
- Gaurav Narula3,2,
- PG Subramanian1,2 and
- Nikhil Patkar1,2,*
- 1Department of Haematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India
- 2Homi Bhabha National Institute (HBNI), Mumbai, India
- 3Pediatric Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
- 4Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
- ↵*Corresponding Author: Correspondence: Dr Nikhil Patkar MD,DNB Clinician Scientist & Professor Wellcome Trust – DBT Senior Fellow Department of Hematopathology, CCE Building, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Maharashtra, India, Pin: 410210, Email: nvpatkar{at}gmail.com Phone: +91-22-27405000
Posted October 17, 2024.
Clinical Relevance and Applicability of the 2022 World Health Organization Classification of Childhood B Lymphoblastic Leukemia in the Context of MRD-Directed Therapy
